24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes

Summary

A better glycemic control is associated with less complications (cardiac diseases, blindness, etcetera) for type 2 diabetic patients. The objective is to study if rosiglitazone may lead to a more regular glycemic pattern with less hyperglycemia and hypoglycemia episodes than with a sulphonylurea (glimepiride).

Timeline

Start

2005-11

Primary completion

2007-10

Completion

2007-10

Outcome

Missed primary endpoint

registry analysis (superiority or other test); Avandamet® (Rosiglitazone/Metformin) vs Glimepiride/Metformin; p = 0.064; Mean Difference (Net) 5.02 (95% CI -0.32 to 10.36); ANCOVA NCT00318656 ↗

registry analysis (superiority or other test); Avandamet® (Rosiglitazone/Metformin) vs Glimepiride/Metformin; p = 0.923; Mean Difference (Net) -0.26 (95% CI -3.37 to 2.85); ANCOVA NCT00318656 ↗

Publications

• Monnier L, Colette C, Comenducci A, Vallee D, Dejager S. Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose? Diabetes Technol Ther. 2012 Oct;14(10):943-50. doi: 10.1089/dia.2012.0045. Epub 2012 Jul 9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Glimepiride	Small molecule	—	—
Subject	Rosiglitazone	Small molecule	—	—
Background	Metformin	Small molecule	—	—

Indications